ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
VolitionRX Limited

VolitionRX Limited (VNRX)

0.7317
0.021
( 2.95% )
Updated: 06:31:07

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.7317
Bid
-
Offer
-
Volume
125,321
0.69 Day's Range 0.75
0.4301 52 Week Range 1.23
Market Cap
Previous Close
0.7107
Open
0.69
Last Trade
100
@
0.7317
Last Trade Time
06:31:07
Financial Volume
US$ 91,296
VWAP
0.728499
Average Volume (3m)
120,329
Shares Outstanding
92,101,479
Dividend Yield
-
PE Ratio
-1.90
Earnings Per Share (EPS)
-0.38
Revenue
775k
Net Profit
-35.32M

About VolitionRX Limited

VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed ... VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy. Show more

Sector
In Vitro,in Vivo Diagnostics
Industry
Mng, Quarry Nonmtl Minerals
Headquarters
Wilmington, Delaware, USA
Founded
2012
VolitionRX Limited is listed in the In Vitro,in Vivo Diagnostics sector of the American Stock Exchange with ticker VNRX. The last closing price for VolitionRX was US$0.71. Over the last year, VolitionRX shares have traded in a share price range of US$ 0.4301 to US$ 1.23.

VolitionRX currently has 92,101,479 shares in issue. The market capitalisation of VolitionRX is US$65.46 million. VolitionRX has a price to earnings ratio (PE ratio) of -1.90.

VNRX Latest News

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update

VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update PR Newswire HENDERSON, Nev., Nov. 8, 2024 Conference call to take place on Friday, November 15 at 8:30...

Volition Appoints Timothy I. Still as Chairman

Volition Appoints Timothy I. Still as Chairman PR Newswire HENDERSON, Nev., Nov. 6, 2024 HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a...

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating

Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating PR Newswire HENDERSON, Nev., Oct. 31, 2024 HENDERSON, Nev., Oct. 31, 2024 /PRNewswire/ -- VolitionRx...

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar

Volition to share new 'NETs in sepsis management' data insights at upcoming webinar PR Newswire HENDERSON, Nev., Oct. 9, 2024 HENDERSON, Nev., Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.141724.01694915250.590.760.581779290.66650491CS
40.00270.370370370370.7290.760.551051930.6504711CS
120.121719.95081967210.610.90.551203290.67727026CS
26-0.1083-12.89285714290.840.90.43011217780.66521123CS
52-0.1194-14.02890377160.85111.230.43011645760.78627527CS
156-2.9183-79.95342465753.654.14010.43011383111.47575894CS
260-4.7683-86.69636363645.57.690.43011846842.74481893CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GNSGenius Group Limited
US$ 1.045
(65.61%)
94.66M
KAPAKairos Pharma Ltd
US$ 1.991
(46.40%)
609.82k
AEAdams Resources and Energy Inc
US$ 37.22
(36.24%)
190.3k
FOXOFOXO Technologies Inc
US$ 0.9005
(29.57%)
260.92M
MSOXAdvisorShares MSOS Daily Leveraged ETF
US$ 0.73
(29.18%)
24.66M
EFSH1847 Holdings LLC
US$ 1.07
(-46.23%)
4.91M
MTNBMatinas Biopharma Holdings Inc
US$ 0.6999
(-22.23%)
358.45k
TOVXTheriva Biologics Inc
US$ 1.4894
(-19.92%)
508.97k
LSFLaird Superfood Inc
US$ 8.43
(-15.62%)
246.52k
NCLNorthann Corp
US$ 0.3404
(-13.82%)
2.07M
FOXOFOXO Technologies Inc
US$ 0.9005
(29.57%)
260.92M
GNSGenius Group Limited
US$ 1.045
(65.61%)
94.66M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 1.739
(-8.23%)
68.17M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 31.30
(-4.49%)
58.41M
FXIiShares China Large Cap
US$ 30.3401
(-3.62%)
53.52M

VNRX Discussion

View Posts
Rayn_Makr Rayn_Makr 4 months ago
215,000 shares traded on7/9/2024 at 11;25 @ $0.60. Lately its been 20,000 a day. I think somebody knows something is up. TWT.
👍️0
Monksdream Monksdream 9 months ago
VNRX under $2
👍️0
Agoura Guy Agoura Guy 9 months ago
BEWARE OF THE STOCK PUMPING CRIMINAL WHO SHORTS HIS OWN PUMPS!!!!!!!

CHECK OUT HIS POSTING HISTORY!!!!!!!


👍️ 1 🚫 1
TrendTrade2016 TrendTrade2016 9 months ago
VNRX...NEW BIO PLAY UNDERWAY WITH A 1.32 TRIGGER UP A HEAD!!!
👍️0
glenn1919 glenn1919 10 months ago
VNRX.......................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 10 months ago
VNRX.............................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 1 year ago
VNRX......................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 1 year ago
VNRX new 52 week low
👍️0
glenn1919 glenn1919 1 year ago
VNRX................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783
👍️0
Disquisition Disquisition 1 year ago
HORRENDOUS DUMPING
👍️0
Monksdream Monksdream 1 year ago
VNRX new 52 week low
👍️0
budgetthis budgetthis 2 years ago
Give me $2.50 !!

$$ VNRX $$
👍️0
Happycoins Happycoins 4 years ago
Seems like very bad news stocks getting hammard premarket.
👍️0
whytestocks whytestocks 4 years ago
News: $VNRX Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test

AUSTIN, Texas , July 14, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company applying its Nu.Q™ Nucleosomics™ technology to develop simple, cost effective blood-based tests for cancer and other diseases, today...

In case you are interested VNRX - Volition Announces Promising Clinical Trials Results for its Novel COVID-19 Triage Test
👍️0
ClayTrader ClayTrader 4 years ago
* * $VNRX Video Chart 07-14-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
maljo maljo 4 years ago
good news today, hope it runs to $5
👍️0
rodman rodman 4 years ago
Whatever happened to the supposed out of the box blood test for a colonoscopy procedure replacement. This company has been a funding animal like a pac-man eating of the $$$$$$$$$'s!
Geez!
rod
👍️0
XenaLives XenaLives 4 years ago
I suspect the patent is about more than COVID...


Introduction
Neutrophils are the most abundant leukocytes in mammals and, as a first line of defense against microbes, they play crucial roles in innate immune responses. The homeostasis of neutrophils is maintained by balancing their short lifespan in the circulation with their regulated release from the bone marrow. Neutrophils have various types of granules, containing hundreds of proteins. These include bactericidal proteins, some of them with important effects on innate and adaptive immune responses, such as a-defensins, the cathelicidin human cationic antimicrobial protein of 18 kDa, and lactoferrin, among others. LL-37, a proteolytic product of human cationic antimicrobial protein of 18 kDa, has important chemotactic and immunostimulatory effects, as discussed below (1).

The mechanisms used by neutrophils to eliminate microbes include phagocytosis, generation of reactive oxygen species (ROS), and the release of microbicidal molecules from granules (degranulation). In 2004, another distinct antimicrobial activity was described: neutrophils extrude a meshwork of chromatin fibers that are decorated with granule-derived antimicrobial peptides and enzymes such as neutrophil elastase (Fig. 1), cathepsin G, and myeloperoxidase (MPO) (2). These structures, called neutrophil extracellular traps (NETs), represent an important strategy to immobilize and kill invading microorganisms. The NET scaffold consists of chromatin fibers with a diameter of 15–17 nm; DNA and histones represent the major NET constituents (2). Mass spectrometry has identified various additional proteins associated with NETs, including components from various types of granules. Although conserved proteins are found in extracellular trap fractions, it is still unclear whether the peptide composition of these structures may vary depending on the specific stimulus that promotes NET formation (3, 4).

Cont..


https://www.jimmunol.org/content/189/6/2689.long
👍️0
XenaLives XenaLives 4 years ago
4/23/20 - Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies

AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.

Full PR:
https://finance.yahoo.com/news/volition-files-patent-nu-q-123000672.html



👍️0
XenaLives XenaLives 4 years ago
Volition Video Gallery:

https://volition.com/press-room/video-gallery
👍️0
XenaLives XenaLives 4 years ago
More eavesdropping:



gordoncamelion wrote on 20.05.20 11:13:27 Entry No. 1.763 (63,747,802) The results from the large lung cancer study should come in Q2 2020. Here are the topics that will come this year. Upcoming Milestones We expect the company to accomplish some of the near-term milestones below: ? Q2 Clinical performance data from individual assays and in the panel combinations across the range of cancers ? Q2 / 3 Clinical data from COVID-19 studies currently underway ? Advance large-scale colorectal and lung cancer trials in Europe, Asia and the US ? Determine the level of tumor associated nucleosomes using mass spectrometry and identify NEW biomarker targets ? Q2 Utilize Nu.Q sequencing to identify tumor of origin and specific mutations ? Q3 Utilize in conjunction with Nu.Q immunoassay approach to enhance performance ? Q4 Launch Nu. Q Vet




https://www.wallstreet-online.de/diskussion/1275261-1761-1770/bluttest-krebserkennung-valitionrx-was
👍️0
XenaLives XenaLives 4 years ago
Eavesdropping:


Labsolute wrote on 21.05.20 17:25:37 Entry No. 1.785 (63.763.840) Reply to entry no .: 63.763.585 by tycoon111 am 05/21/20 16:55:36 I am optimistic from the bottom up and may be concerned with my investments, maybe that's the reason And: the burn rate is great, nothing is too high !! Capital increases are also absolutely normal for such companies. Volition has never had any problems getting fresh cash in the past and has always been supported by the state. You can not be blamed for burning the shareholders' money senselessly! And slowly what needs to be monetized is your opinion as so I take on young impatient small shareholders. I see the data that was published a week ago and I know that such a diagnosis no other company in the world can - not at Stage1 and not at the price and time required. And in my opinion it will stay that way for a long time! I do not know whether the price climbs up or down as your question was - but I see a ridiculous market capitalization which can only increase tenfold in the short term (vet / Lung china / COVID) with just one successful piece of the puzzle and on the other hand I see a stable balance sheet a lot of cash and competitors who all still need a lot of time! So an excellent change risk ratio, even if small cap very risky!





Labsolute wrote on 23.05.20 14:18:01 Entry No. 1.789 (63.779.455) no topic - welcome to high risk - high reward. You have to get along with the Vola - especially difficult as an ETF investor. Always think of fear vs greed and rationally rethink everything in difficult phases. We are in a wild market phase: from V-recovery to deepest depression, everything is in the room - if you have already felt uncomfortable, rethink the position size. Otherwise there is now more than enough cash in the company to survive this phase and we can look forward to further data and news this year. Reynolds directly secured a small package for $ 2.75. Think that calms many people again.



https://www.wallstreet-online.de/diskussion/1275261-1781-1790/bluttest-krebserkennung-valitionrx-was
👍️0
XenaLives XenaLives 4 years ago
EIGHT CORPORATION LIMITED REPORTS 23.8% STAKE IN VOLITIONRX LTD AS OF MAY 29 - SEC FILING


HEALTHCAREJUNE 2, 2020 / 4:08 PM / UPDATED 13 HOURS AGO
BRIEF-Eight Corporation Limited Reports 23.8% Stake In Volitionrx Ltd As Of May 29
1 MIN READ

June 2 (Reuters) - VolitionRX Ltd:

* EIGHT CORPORATION LIMITED REPORTS 23.8% STAKE IN VOLITIONRX LTD AS OF MAY 29 - SEC FILING

* EIGHT CORPORATION LTD-ON MAY 29, CONTACTED VOLITIONRX’S BOARD TO REQUEST EXPANSION OF BOARD AS WELL AS APPOINTMENT OF 3 DIRECTORS SELECTED BY THEM

* EIGHT CORPORATION LTD - REQUESTED VOLITIONRX’S BOARD FORM A COMMITTEE TO EVALUATE, AMONG OTHER THINGS, BUSINESS STRATEGY AND SUCCESSION PLANS

* EIGHT CORPORATION LTD - HAD PREVIOUSLY REPORTED 29.2% STAKE IN VOLITIONRX AS OF MAY 7 Source text: (bit.ly/2Y8YnEv) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.




https://uk.reuters.com/article/brief-eight-corporation-limited-reports/brief-eight-corporation-limited-reports-238-stake-in-volitionrx-ltd-as-of-may-29-idUKFWN2DF0O6
👍️0
XenaLives XenaLives 4 years ago
Epigenetic change has also compromised our immune systems. I believe this is the primary reason why seniors are dying of COVID in the nursing homes.

Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

https://volition.com/press-room/press-releases/volition-announces-cameron-reynolds-president-and-chief-executive-officer-invited-as-presenter-at-maxims-covid-19-virtual-conference
👍️0
XenaLives XenaLives 4 years ago
Epigenetics is an issue in much more than cancer.

I suspect that this is just an initial focus for this company but will have to do more research.
👍️0
XenaLives XenaLives 4 years ago
Only 8% insty ownership but this bears looking into:


2020-05-07 13D/A Eight Corp Ltd 12,045,332 29.20
2019-08-01 13D Cotterford Co Ltd 12,041,570 29.30
2019-02-25 13G/A Hever Investments Ltd 11,877,476 29.40
2019-02-14 13G/A Lagoda Investment Management, L.P. 1,643,714 4.70
2019-02-11 13D/A Innes Guy Archibald 1,875,701 5.30
2018-11-09 13D/A Faulkes Martin Charles 1,977,284 5.60
2018-11-09 13D/A Reynolds Cameron John 2,562,967 7.20
2017-02-08 13G/A MANCHESTER MANAGEMENT CO LLC 1,212,159 4.60
2016-12-29 13D Hunt David 63,440,000 62.30
👍️0
XenaLives XenaLives 4 years ago
Intriguing stock, from the Ibox:


Nucleosomics® Accessing the Epigenome



The company’s NuQ® range of research uses only epigenetic research tools, and is available to life science researchers in a familiar and accessible format – the simple immunoassay.
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX this little bull is about to blow up. The cancer play of the year
👍️0
ClayTrader ClayTrader 5 years ago
* * $VNRX Video Chart 09-25-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $VNRX Video Chart 09-24-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX amazing strength!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX OMG look at her run!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX here she goes...this monster is going to blow up!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX boom...a monster!!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX boom and halt!!! come on baby!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX boom Out of the gate!
👍️0
Golden Cross Golden Cross 5 years ago
VNRX Daily Chart

👍️0
Golden Cross Golden Cross 5 years ago
96% Technical BUY Rating

https://www.barchart.com/stocks/quotes/VNRX/opinion
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX about to become a low float monster. Just wait for the volume to really kick in
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX wowza what a close..morning call went out!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX look at her go..oh my lord!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX friday monster surge...this one is gonna be fun!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
Here we go...VNRX the next bio beast!!!
👍️0
TrendTrade2016 TrendTrade2016 5 years ago
VNRX new nasy jazzy bio wonder play...watch this beast take off!!
👍️0
whytestocks whytestocks 5 years ago
News: $VNRX Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

AUSTIN, Texas , Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.Q TM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin....

Find out more VNRX - Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
👍️0
pottsville pottsville 5 years ago
Not today tho.. Chuckle
👍️0
pottsville pottsville 5 years ago
I do like what I'm seeing here
👍️0
whytestocks whytestocks 5 years ago
News: $VNRX Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

AUSTIN, Texas , July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase $4.8 million in aggregate amount of shar...

Read the whole news Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
👍️0
whytestocks whytestocks 5 years ago
News: $VNRX VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

AUSTIN, Texas , July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, B...

In case you are interested VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
👍️0
wiltonio wiltonio 6 years ago
Cotterford Co Ltd has filed a new 13G, reporting 29.4% ownership in $VNRX - https://fintel.io/so/us/vnrx and https://fintel.io/i/cotterford
👍️0

Your Recent History

Delayed Upgrade Clock